Business
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik
NEW YORK, January 13, 2026--Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025.
About this update from Booz Allen Hamilton Holding Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/4bbbcfcbcd696b5ec49f5cd8619f2e29"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xU.mtonpwBYKIh_IrvB.QQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTcyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4bbbcfcbcd696b5ec49f5cd8619f2e29","width":480,"height":360}},"lazy":false},{"type":"text","content":"NEW YORK, January 13, 2026--(BUSINESS WIRE)--Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025.","length":301,"tagName":"p"},{"type":"text","content":"Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh.","length":608,"tagName":"p"},{"type":"text","content":"The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, "R&D organizations face an extremely complex world right now. Artificial intelligence is transforming all aspects of R&D, pressure to keep pipelines full is driving companies to seek new sources of innovation, and clinical trial complexity is rising. R&D leaders have to stay ahead of all those factors while simultaneously moving assets through development."","length":525,"tagName":"p"},{"type":"text","content":"She says that the new practice helps R&D organizations successfully navigate this difficult environment. "Our capabilities span from innovation and discovery, through clinical development, to regulatory strategy and post-market surveillance. We help ens...